Prellis Biologics is a pioneering company in the field of organ and tissue engineering. The company specializes in creating biomimetic 3D cell culture scaffolds that allow for Matrigel-free, low hypoxia large organoid culture. These scaffolds enable researchers to grow human primary cells, including neurons, liver, immune cells, and patient-derived breast cancer cells, for extended periods with minimal hypoxia and spontaneous formation of complex 3D architecture. The technology is designed to tightly control the micro-scale architecture of 3D cultures, resulting in more consistent and reliable outcomes, which translates to quicker results, lower costs, and the ability to conduct more tests. Prellis Biologics' biocompatible scaffolds are built at speeds 100 times faster than any other technology, making them a valuable asset for academic and pharmaceutical research labs. The company has also generated 300 human antibodies with neutralization potential against SARS-CoV-2 and is pursuing the development of treatments and preventative therapies for COVID-19. Prellis Biologics operates in the biotechnology market, serving academic institutions and pharmaceutical companies. The business model involves selling their advanced scaffolds to research labs, which use them to produce large 3D organoids and improve tissue engraftment in transplant models. The company generates revenue through the sale of these scaffolds and related products to over 50 research labs worldwide.

Keywords: biomimetic, 3D cell culture, scaffolds, organoid culture, low hypoxia, human primary cells, biocompatible, SARS-CoV-2 antibodies, biotechnology, research labs.